1200 related articles for article (PubMed ID: 9879825)
21. The BCR/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukemia patients.
Nakajima H; Zhao R; Lund TC; Ward J; Dolan M; Hirsch B; Miller JS
J Immunol; 2002 Jan; 168(2):643-50. PubMed ID: 11777957
[TBL] [Abstract][Full Text] [Related]
22. Integrin-mediated regulation of hematopoiesis: do BCR/ABL-induced defects in integrin function underlie the abnormal circulation and proliferation of CML progenitors?
Verfaillie CM; Hurley R; Lundell BI; Zhao C; Bhatia R
Acta Haematol; 1997; 97(1-2):40-52. PubMed ID: 8980609
[TBL] [Abstract][Full Text] [Related]
23. No correlation between locations of bcr breakpoints and clinical states in Ph1-positive CML patients.
Ogawa H; Sugiyama H; Soma T; Masaoka T; Kishimoto S
Leukemia; 1989 Jul; 3(7):492-6. PubMed ID: 2733454
[TBL] [Abstract][Full Text] [Related]
24. Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia--potential clinical significance.
Inokuchi K; Yamaguchi H; Tarusawa M; Futaki M; Hanawa H; Tanosaki S; Dan K
Leukemia; 2002 Feb; 16(2):170-7. PubMed ID: 11840282
[TBL] [Abstract][Full Text] [Related]
25. Philadelphia chromosome-negative chronic myelogenous leukemia without breakpoint cluster region rearrangement: a chronic myeloid leukemia with a distinct clinical course.
Kurzrock R; Kantarjian HM; Shtalrid M; Gutterman JU; Talpaz M
Blood; 1990 Jan; 75(2):445-52. PubMed ID: 2403827
[TBL] [Abstract][Full Text] [Related]
26. Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice.
Skorski T; Nieborowska-Skorska M; Wlodarski P; Zon G; Iozzo RV; Calabretta B
Blood; 1996 Aug; 88(3):1005-12. PubMed ID: 8704208
[TBL] [Abstract][Full Text] [Related]
27. The molecular biology of chronic myeloid leukaemia.
Melo JV
Leukemia; 1996 May; 10(5):751-6. PubMed ID: 8656667
[TBL] [Abstract][Full Text] [Related]
28. Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL.
Sattler M; Salgia R
Cytokine Growth Factor Rev; 1997 Mar; 8(1):63-79. PubMed ID: 9174663
[TBL] [Abstract][Full Text] [Related]
29. Chronic myeloid leukemia stem cells.
Jamieson CH
Hematology Am Soc Hematol Educ Program; 2008; ():436-42. PubMed ID: 19074122
[TBL] [Abstract][Full Text] [Related]
30. Role of abnormal integrin-cytoskeletal interactions in impaired beta1 integrin function in chronic myelogenous leukemia hematopoietic progenitors.
Bhatia R; Munthe HA; Verfaillie CM
Exp Hematol; 1999 Sep; 27(9):1384-96. PubMed ID: 10480429
[TBL] [Abstract][Full Text] [Related]
31. Gene therapy for chronic myelogenous leukemia (CML): a retroviral vector that renders hematopoietic progenitors methotrexate-resistant and CML progenitors functionally normal and nontumorigenic in vivo.
Zhao RC; McIvor RS; Griffin JD; Verfaillie CM
Blood; 1997 Dec; 90(12):4687-98. PubMed ID: 9389683
[TBL] [Abstract][Full Text] [Related]
32. BCR/ABL- CD34(+)HLA-DR- progenitor cells in early chronic phase, but not in more advanced phases, of chronic myelogenous leukemia are polyclonal.
Delforge M; Boogaerts MA; McGlave PB; Verfaillie CM
Blood; 1999 Jan; 93(1):284-92. PubMed ID: 9864172
[TBL] [Abstract][Full Text] [Related]
33. [Bcr-Abl inhibition as molecular therapy approach in chronic myeloid leukemia].
Buchdunger E
Med Klin (Munich); 2002 Jan; 97 Suppl 1():2-6. PubMed ID: 11831067
[TBL] [Abstract][Full Text] [Related]
34. Successful treatment of lymphoid blastic crisis in chronic myelogenous leukemia with the additional bcr/abl transcript using imatinib-combined chemotherapy and high-dose chemotherapy with allogeneic bone marrow stem cell transplantation.
Kawano N; Okuda S; Yoshida S; Kugimiya H; Ito M; Horikawa N; Chosa N; Hisakata T; Fukudome T; Sakurai R; Yamashita K; Ueda A; Kanda Y
Int J Hematol; 2011 Dec; 94(6):561-6. PubMed ID: 22057509
[TBL] [Abstract][Full Text] [Related]
35. [Autologous bone marrow transplantation for patients with chronic myelogenous leukemia after in vitro purging of the graft with bcr/abl antisense oligodeoxynucleotides].
Sun J; Wu B; Liu Q; Feng R; Liu X; Meng F; Zhou S
Zhonghua Xue Ye Xue Za Zhi; 2000 Aug; 21(8):400-2. PubMed ID: 11877009
[TBL] [Abstract][Full Text] [Related]
36. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells.
Skorski T; Kanakaraj P; Nieborowska-Skorska M; Ratajczak MZ; Wen SC; Zon G; Gewirtz AM; Perussia B; Calabretta B
Blood; 1995 Jul; 86(2):726-36. PubMed ID: 7606002
[TBL] [Abstract][Full Text] [Related]
37. Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation.
Wetzler M; Talpaz M; Van Etten RA; Hirsh-Ginsberg C; Beran M; Kurzrock R
J Clin Invest; 1993 Oct; 92(4):1925-39. PubMed ID: 8408645
[TBL] [Abstract][Full Text] [Related]
38. Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia.
Phan CL; Megat Baharuddin PJ; Chin LP; Zakaria Z; Yegappan S; Sathar J; Tan SM; Purushothaman V; Chang KM
Cancer Genet Cytogenet; 2008 Jan; 180(1):60-4. PubMed ID: 18068536
[TBL] [Abstract][Full Text] [Related]
39. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
Neviani P; Santhanam R; Oaks JJ; Eiring AM; Notari M; Blaser BW; Liu S; Trotta R; Muthusamy N; Gambacorti-Passerini C; Druker BJ; Cortes J; Marcucci G; Chen CS; Verrills NM; Roy DC; Caligiuri MA; Bloomfield CD; Byrd JC; Perrotti D
J Clin Invest; 2007 Sep; 117(9):2408-21. PubMed ID: 17717597
[TBL] [Abstract][Full Text] [Related]
40. Characterization and selection of benign stem cells in chronic myeloid leukemia.
Lemoli RM
Haematologica; 1993; 78(6):393-400. PubMed ID: 8175034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
